<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04628507</url>
  </required_header>
  <id_info>
    <org_study_id>Genomic Prediction Inc 632</org_study_id>
    <nct_id>NCT04628507</nct_id>
  </id_info>
  <brief_title>Cell Free Preimplantation Genetic Testing</brief_title>
  <official_title>Evaluation of Cell Free Preimplantation Genetic Testing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genomic Prediction Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genomic Prediction Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to develop preimplantation genetic testing methods from embryo culture media&#xD;
      (cell free). Genetic testing of culture media will be compared to conventional methods based&#xD;
      on embryo biopsies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Consenting patients will receive standard clinical IVF and PGT. Culture media from embryos&#xD;
      will be collected for analysis. Collection of media will include laser assisted collapse of&#xD;
      the blastocyst on day 5, 6, or 7 in order to release blastocoel fluid into the culture media.&#xD;
      Embryos diagnosed as aneuploid or monogenic disorder affected (abnormal embryos) will be&#xD;
      donated for additional analysis with patient consent.&#xD;
&#xD;
      Results obtained from culture media will not be provided to the patients. The information&#xD;
      obtained from cf-PGT will be compared to results obtained from embryo biopsies obtained as&#xD;
      part of routine PGT and evaluated for concordance and reliability. Abnormal embryos will be&#xD;
      rebiopsied (~3 to 4 times) to evaluate concordance with cf-PGT and the original clinical&#xD;
      trophectoderm biopsy PGT results.&#xD;
&#xD;
      All cases will be labelled using a 5-digit barcode and embryo number or saliva source code.&#xD;
      Because PGT will be conducted under clinical regulatory approval (CAP and CLIA), patient&#xD;
      information will be protected under HIPAA guidelines, including sending reports in encrypted&#xD;
      secure email per standard operating procedures. All publications and presentations will&#xD;
      maintain de-identification of any patient data used.&#xD;
&#xD;
      Patients may withdraw from the study at any time by contacting the principal investigator of&#xD;
      their respective recruiting site. They will continue to receive standard of care through&#xD;
      their treating IVF center. A recruitment target of 200 patients is intended for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">January 11, 2021</start_date>
  <completion_date type="Anticipated">January 11, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 11, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Concordance with PGT</measure>
    <time_frame>14 dyas</time_frame>
    <description>Concordance rates with PGT diagnosis from trophectoderm biopsies</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Infertility, Female</condition>
  <condition>Infertility, Male</condition>
  <arm_group>
    <arm_group_label>Patients undergoing IVF</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Spent media collection</intervention_name>
    <description>Embryo spent culture media, otherwise discarded as per standard of care, is collected once embryos have completed in vitro culture.</description>
    <arm_group_label>Patients undergoing IVF</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Saliva samples, embryo spent culture medium, and leftover amplification product from embryo&#xD;
      biopsies.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients undergoing IVF electing to utilize LifeView testing who consented for embryo spent&#xD;
        media collection and analysis.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients undergoing IVF electing to utilize LifeView testing (PGT) will be offered&#xD;
             participation in this study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Genomic Prediction Clinical Laboratory</name>
      <address>
        <city>North Brunswick</city>
        <state>New Jersey</state>
        <zip>08902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 9, 2020</study_first_submitted>
  <study_first_submitted_qc>November 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2020</study_first_posted>
  <last_update_submitted>February 5, 2021</last_update_submitted>
  <last_update_submitted_qc>February 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PGT</keyword>
  <keyword>Noninvasive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
    <mesh_term>Infertility, Male</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

